NextCure is a biopharmaceutical company focused on discovering and developing next-generation immuno-oncology-based drugs.
It is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immune medicines to treat cancer and other immune-related diseases by restoring normal immune function.
The immune system is viewed holistically and, rather than targeting one specific immune cell type, it focuses on understanding biological pathways, the interactions of cells and the role each interaction plays in an immune response.
Through proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology, or FIND-IO, platform, the study of various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immune medicines.
The company is focused on patients who do not respond to current therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies.
Next Cure Founder’s Profile
- Dr. Lieping Chen is the scientific founder of NextCure and the United Technologies Corporation Professor in Cancer Research and Professor of Immunobiology, Dermatology, and Medicine (Medical Oncology) at Yale University.
- He is also the Co-Director of the Cancer Immunology Program at Yale Cancer Center.
- Dr. Chen is a pioneer in the field of lymphocyte co-stimulation and co-inhibition. In 1992, Dr. Chen was the first to discover “co-stimulation of tumor immunity” and to use co-stimulatory molecules to treat cancer and other diseases.
- NextCure is funded by 16 investors. Lilly Asia Ventures and Surveyor Capital are the most recent investors.
- In its recent funding, the company raised $93 million Series B equity financing. The financing was led by Hillhouse Capital Management and Quan Capital and included Bay City Capital, Surveyor Capital (a Citadel company), Ping An Ventures, Taiho Ventures LLC, ArrowMark Partners, and NS Investment.
- All existing investors also participated in this financing, including Canaan Partners, Lilly Asia Ventures, OrbiMed Advisors LLC, Pfizer Inc., Sofinnova Ventures and Alexandria Venture Investments.
- Additionally, Eli Lilly and Company invested $15 million in this financing in conjunction with the discovery and development partnership announced on November 5, 2018.
- Cash, cash equivalents, and marketable securities, excluding restricted cash, as of December 31, 2019, were $334.6 million, compared to $135.2 million as of December 31, 2018. This increase was primarily due to $238.4 million net proceeds from public offerings partially offset by cash used to fund operations of $35.6 million.
- Revenue from the research and development arrangement was $2.0 million and $6.3 million for the three months and the full year ended December 31, 2019, respectively.
Current scenario and Future plans
Shares of NextCure (NASDAQ: NXTC), a clinical-stage biopharmaceutical company developing new cancer drugs, exploded higher last month.
Updated clinical trial results from a handful of non-small cell lung cancer patients sent the biotech stock 225.8% higher as of 3:22 p.m. by recent news.
In March the company said that NC318 shrank tumors for one lung-cancer patient treated in a proof-of-concept study.
The stock took off like a rocket today when investors learned that one patient achieved complete remission, another experienced tumor shrinkage, and three more haven’t gotten any worse.
The experimental cancer drug’s target, S15, shuts down immune-system attacks against foreign cells before neighboring healthy cells get caught in the fray.
This pathway is often exploited by cancer cells, which allows tumors to grow unchecked. If this sounds familiar, it’s because blockbuster cancer therapies like Keytruda work similarly, by aiming at a different target called PD-L1.
The next cure controls the destiny of two promising immuno-oncology drug candidates: NC318 and NC410. Most savvy investors probably attribute the bulk of the company’s valuation to these programs, and Lilly never had rights to them.
“NC318 is the first antibody-drug candidate developed at NextCure to enter clinical trials, marking an exciting milestone for our company,” says Michael Richman, CEO of NextCure.
“The trial marks a major advancement in our plan to develop our pipeline of next-generation immune medicines for cancer patients who do not respond to currently approved therapies.”
S15 is a novel immunomodulatory target expressed on a restricted set of myeloid cells in the tumor microenvironment and on certain tumor types including lung, ovarian and head, and neck cancers.
Preclinical research shows that S15 promotes the survival and differentiation of suppressive myeloid cells and negatively regulates T cell function, allowing cancer growth.
NextCure is a clinical-stage biopharmaceutical company committed to discovering next-generation novel, first-in-class immune medicines to treat cancer and other immune-related diseases by restoring normal immune function.
Nextcure views the immune system holistically and, rather than target one specific immune cell type, immune understanding of biological pathways, the interactions of cells and the role each interaction plays in an immune response.
NextCure biopharmaceutical company focused on discovering and developing next-generation first-in-class immune medicines for cancer and other diseases.
Our novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immune medicines.
Our initial focus is to bring hope and new treatments to patients who do not respond to current cancer therapies.